Clinical Trials Logo

Filter by:
NCT ID: NCT04747613 Recruiting - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria

Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria

Start date: July 27, 2021
Phase: Phase 3
Study type: Interventional

This study is an open-label, single arm, multicenter, roll-over extension study to characterize long-term safety, tolerability and efficacy of iptacopan and to provide access to iptacopan to patients with PNH who have completed Novartis-sponsored Phase 2 or 3 studies with iptacopan

NCT ID: NCT04745702 Enrolling by invitation - Diabetes Clinical Trials

Food Based Intervention Rich in Plant Components to Improve Metabolic Health in Prediabetics (FBIP) Study

Start date: November 2, 2020
Phase: N/A
Study type: Interventional

The estimated prevalence of type 2 diabetes and prediabetes in Singapore will be approximately 20% and 25% respectively by the year 2035. Therefore, effective population based interventions are urgently warranted to halt this burden. Lifestyle intervention is the cornerstone of diabetes prevention and even remission. For example, dietary patterns such as the Mediterranean diet, Dietary Approaches to Stop Hypertension (DASH) diet etc. have all been shown to reduce risk of type 2 diabetes incidence. Therefore, given the successful utility of various dietary patterns, this randomized controlled trial will investigate the effectiveness of a food based dietary intervention, within an Asian dietary context, using legumes, low glycemic index (GI) starches (i.e., rice, noodles etc.), healthier vegetable oil blend as well as herbs and spices to improve various markers metabolic health, including glucose homeostasis in individuals with prediabetes.

NCT ID: NCT04745403 Recruiting - Clinical trials for Hepatocellular Carcinoma

Redirected HBV-Specific T Cells in Patients With HBV-related HCC (SAFE-T-HBV)

SAFE-T-HBV
Start date: May 20, 2022
Phase: Phase 1
Study type: Interventional

This is a single center, single arm and open-label study to determine the safety of mRNA modified HBV-TCR redirected T-cells and to analyze the changes in tumor microenvironment caused by these HBV-TCR redirected T-cells in subjects with HBV-related HCC who are not amenable to/failed conventional treatment.

NCT ID: NCT04742478 Recruiting - Clinical trials for Coronary Artery Calcification

ROVUS Asia Registry (Evaluate Safety and Effectiveness of Rotational Atherectomy and Intravascular Ultrasound for Heavily Calcified Coronary Lesion)

ROVUS
Start date: March 10, 2021
Phase:
Study type: Observational [Patient Registry]

Rotablation with or without other calcium debulking therapies is a safe adjunctive procedure for patients with severe coronary calcification requiring Percutaneous Coronary Intervention (PCI).

NCT ID: NCT04742192 Completed - Clinical trials for Non-small Cell Lung Cancer

Non-interventional, Prospective Study to Determine Prevalence of EGFR Mutations in Non-small Cell Lung Cancer

EARLY-EGFR
Start date: March 4, 2021
Phase:
Study type: Observational

This prospective, multicountry, multicentre, non-interventional study plans to include patients who have undergone surgery for early-stage (IA to IIIB on the basis of pathologic criteria) non-squamous NSCLC up to 6 weeks prior to enrolment into the study. The main objective of this study is to determine the prevalence of EGFRm in patients with surgically resected early-stage (IA to IIIB) non-squamous NSCLC as there are limited data on its prevalence in this patient population.

NCT ID: NCT04740931 Completed - Macular Edema Clinical Trials

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion

COMINO
Start date: March 2, 2021
Phase: Phase 3
Study type: Interventional

This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled, parallel-group study evaluating the efficacy, safety, and pharmacokinetics of faricimab administered by intravitreal (IVT) injection at 4-week intervals until Week 24, followed by a double-masked period of study without active control to evaluate faricimab administered according to a personalized treatment interval (PTI) dosing regimen in patients with macular edema due to central retinal vein occlusion (CRVO) or hemiretinal vein occlusion (HRVO).

NCT ID: NCT04740905 Completed - Macular Edema Clinical Trials

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion

BALATON
Start date: March 2, 2021
Phase: Phase 3
Study type: Interventional

This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled, parallel-group study evaluating the efficacy, safety, and pharmacokinetics of faricimab administered by intravitreal (IVT) injection at 4-week intervals until Week 24, followed by a double-masked period of study without active control to evaluate faricimab administered according to a personalized treatment interval (PTI) dosing regimen in participants with macular edema due to branch retinal vein occlusion (BRVO).

NCT ID: NCT04740671 Active, not recruiting - Clinical trials for Age Related Macular Degeneration

A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD

Start date: July 1, 2021
Phase: Phase 3
Study type: Interventional

This study will compare the efficacy and safety of HLX04-O administered by intravitreal injection (IVT) with ranibizumab in patients with active wAMD.

NCT ID: NCT04738708 Recruiting - Genetic Counselling Clinical Trials

Telegenetics or In-Person Genetic Counselling

Start date: February 1, 2021
Phase:
Study type: Observational

This study aims to compare clinical outcomes (informed choice and genetic counselling outcomes) and cost (provider and patient time, travel, and telehealth platform) between telegenetics and in-person genetic counselling.

NCT ID: NCT04731662 Active, not recruiting - Sleep Clinical Trials

Performance, Mood, and Brain and Metabolic Functions During Different Sleep Schedules

STAVAR
Start date: February 1, 2021
Phase: N/A
Study type: Interventional

This proposed project will investigate whether a variable or a stable sleep schedule will be more effective in minimizing neurobehavioural and metabolic deficits when total sleep opportunity across two weeks is below the recommended sleep duration. In this laboratory-based, stay-in study, 60 young adults will be randomized into 1 of 3 groups. After 2 nights of 8-h time-in-bed (TIB) that simulate longer sleep opportunities typical of weekends, the stable short sleep group will have a 6-h TIB in each of the following 5 'weeknights' (8866666). The variable short sleep group (8884846) will also have a total TIB of 30h during the 'weeknights', although TIB varies across the 'weeknights'. The nightly TIB of the well-rested control group will be 8h (8888888). These manipulations will repeat in the second week, enabling the tracking of outcome measures during recurrent weeks of sleep restriction on 'weekdays' and extension on 'weekends'. A test battery assessing basic cognitive functions and mood will be administered 5 times a day. A long-term memory encoding task will be administered after week 1. A functional Magnetic Resonance Imaging (fMRI) brain scan, and an Oral Glucose Tolerance Test (OGTT) will be conducted after the second 'weekend' night and after the last 'weeknight' each week. Continuous glucose monitoring will be conducted throughout the experiment. Sleep will be measured every night with polysomnography.